MONROVIA, Calif., June 14, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the Company will host an Analyst Day on Tuesday, June 28, 2016, from 8:30 a.m. - 11:30 a.m. ET in New York City.

During the Analyst Day, members of Xencor's management team will provide updates on the Company's XmAb^®5871 and XmAb^®7195 development programs, as well as on its XmAb^® bispecific pipeline including XmAb^®14045 and XmAb^®13676. 

Guest speakers scheduled to attend and present at the event include:

• Michael Curran, Ph.D.
  Assistant Professor, Department of Immunology, The University of Texas MD Anderson Cancer Center
  Member, Graduate Faculty, The University of Texas Graduate School of Biomedical Science
• Paul Hamlin, M.D.
  Clinical Director, Lymphoma Outpatient Unit and Chief, Basking Ridge Medical Oncology Service, Memorial Sloan Kettering Cancer Center

Webcast Information
A live audio webcast of the presentation will be available under the "Events & Presentations" section in the Investors section of the Company's website located at http://investors.xencor.com/events.cfm. A replay of the presentations will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days following the presentations.

About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Currently, nine candidates that have been engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's internally-discovered programs include: XmAb5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb7195 in Phase 1a development for the treatment of asthma and allergic diseases; and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Amgen, Merck, Janssen R&D LLC, Alexion, Novo Nordisk and Boehringer Ingelheim. For more information, please visit www.xencor.com.    

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/xencor-to-host-analyst-day-and-webcast-on-june-28-2016-300284004.html

SOURCE Xencor, Inc.